Michael Byrnes
Independent DirectorMr. Michael Byrnes, MBA, also known as Mike, is Chief Financial Officer of Fore Biotherapeutics Inc. from August 2024. He has M.B.A. from California State University, East Bay, B.S. in Finance from Santa Clara University. He is Independent Director of CERo Therapeutics Holdings, Inc. from February 14, 2024. He serves as Director of CERo Therapeutics, Inc. from February 2024. He serves as Chief Financial Officer of FORE Biotherapeutics since August 2024. He was Chief Financial Officer of eFFECTOR Therapeutics, Inc. since December 2020 until June 21, 2024. Prior to joining eFFECTOR Therapeutics, he was Senior Vice President of Finance at Principia Biopharma, Inc. which was acquired by Sanofi in September 2020. Prior to that, He served as Chief Financial Officer of Alkahest, Inc. from May 2018 to January 2020 and Chief Financial Officer of Ocera Therapeutics, Inc. from December 2014 until is acquisition by Mallinckrodt Pharmaceuticals in December 2017. He has been Controller of Perseid Therapeutics LLC since March 2010 and is responsible for Perseid's financial operations and strategy with support from Maxygens finance team. He served as Corporate Controller of Maxygen, Inc. from March 2010 to December 2014 and prior to that, held finance positions of increasing responsibility from 2000 to 2010 with NeurogesX, Inc. Lipid Sciences, Inc. and ADAC Laboratories, Inc. From June 2007 to March 2010, he served in financial roles of increasing responsibility, as Director of Finance for NeurogesX, Inc. From December 2002 to June 2007, he served as Finance and Accounting Manager for Lipid Sciences Inc. His experience also includes a variety of accounting and financial roles from 1996 to 2002 at ADAC Labs and Bay View Capital Corporation. He received a B.S.C. in Finance from Santa Clara University and an M.B.A. from California State University, Hayward.
Positions
- Company NameCERo Therapeutics Holdings, Inc.Stock CodeCEROPositionIndependent DirectorRelated Securities
